Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy

Diagnostic Pathology

Dadong Wang³  Boan Li²  JingHui Dong²  Bo Ren²  ZhaoHai Wang²  Ruisheng Li²  Lingxiang Yu²  Lu Xiong¹  XiaoDong Guo² 

[1] Beijing Institute of Radiation Medicine, Beijing 100850, China;302 Hospital of PLA, Beijing 100039, China;Department of Hepatobiliary and Pancreaticosplenic Surgery, the First Affiliated Hospital of General Hospital of PLA, Beijing 100048, China

关键词: Prognosis;    Tumor progression;    Expression;    Nucleolin;    Hepatocellular carcinoma;   

Others  :  1149902
DOI  :  10.1186/s13000-014-0175-y

 received in 2014-05-20, accepted in 2014-08-23,  发布年份 2014

【 摘 要 】

Background

Nucleolin, as a multifunctional protein, has been demonstrated to play an oncogenic role in human hepatocellular carcinoma (HCC). The aim of this study was to investigate the expression pattern of nucleolin in HCC and determine its correlation with tumor progression and prognosis.

Methods

Nucleolin expression at both mRNA and protein levels in HCC and adjacent nonneoplastic tissues were respectively detected by quantitative real time polymerase chain reaction (Q-PCR), immunohistochemistry and western blotting.

Results

Nucleolin expression, at both mRNA and protein levels, was significantly higher in HCC tissues than in the adjacent nonneoplastic tissues (both P?

Conclusion

These results showed that the markedly and consistently increasing expression of nucleolin may be associated with aggressive characteristics of HCC, and implied that nucleolin expression may serve as a promising biochemical marker for predicting the clinical outcome of patients with this malignancy.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_175 webcite.

【 授权许可】

   
2014 Guo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Dhir M, Lyden ER, Smith LM, Are C: Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. HPB (Oxford) 2012, 14:635-645.
• [3]Zhu AX: Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol 2012, 39:493-502.
• [4]Tanaka S, Arii S: Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 2012, 39:486-492.
• [5]Yang H, Xiong F, Wei X, Yang Y, McNutt MA, Zhou R: Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett 2010, 294:236-244.
• [6]Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, Sabichi AL, Ao X, Maeng H, Samaniego F: Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood 2013, 121:4729-4739.
• [7]Koutsioumpa M, Papadimitriou E: Cell surface nucleolin as a target for anti-cancer therapies. Recent Pat Anticancer Drug Discov 2014, 9:137. 52
• [8]Schokoroy S, Juster D, Kloog Y, Pinkas-Kramarski R: Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death. PLoS One 2013, 8:e75269.
• [9]Yang X, Xu Z, Li D, Cheng S, Fan K, Li C, Li A, Zhang J, Feng M: Cell surface nucleolin is crucial in the activation of the CXCL12/CXCR4 signaling pathway. Tumour Biol 2014, 35:333-338.
• [10]Fujiki H, Watanabe T, Suganuma M: Cell-surface nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands. J Cancer Res Clin Oncol 2014, 140:689-699.
• [11]Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med 2013, 210:951-968.
• [12]Qiu W, Zhou F, Zhang Q, Sun X, Shi X, Liang Y, Wang X, Yue L: Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer. APMIS 2013, 121:919-925.
• [13]Zhao H, Huang Y, Xue C, Chen Y, Hou X, Guo Y, Zhao L, Zh H, Huang Y, Luo Y, Zhang L: Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer. PLoS One 2013, 8:e54674.
• [14]Grinstein E, Wernet P: Cellular signaling in normal and cancerous stem cells. Cell Signal 2007, 19:2428-2433.
• [15]Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z: Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials 2014, 35:3840-3850.
• [16]Ridley L, Rahman R, Brundler MA, Ellison D, Lowe J, Robson K, Prebble E, Luckett I, Gilbertson RJ, Parkes S, Rand V, Coyle B, Grundy RG: Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol 2008, 10:675-689.
• [17]Bao H, Song P, Liu Q, Liu Y, Yun D, Saiyin H, Du R, Zhang Y, Fan H, Yang P, Chen X: Quantitative proteomic analysis of a paired human liver healthy versus carcinoma cell lines with the same genetic background to identify potential hepatocellular carcinoma markers. Proteomics Clin Appl 2009, 3:705-719.
• [18]Meng GZ, Xiao SJ, Zeng SE, Li YQ: Downregulation of cell-surface-expressed nucleolin inhibits the growth of hepatocellular carcinoma cells in vitro. Zhonghua Zhong Liu Za Zhi 2011, 33:23-27.
• [19]Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF, Baker T, Wang E, Gupta R, Nayar R, Benson AB 3rd, Abecassis M, Omary R, Salem R: Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 2011, 54:695-704.
• [20]Pirisi M, Leutner M, Pinato DJ, Avellini C, Carsana L, Toniutto P, Fabris C, Boldorini R: Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens. Arch Pathol Lab Med 2010, 134:1818-1822.
• [21]Durand F, Valla D: Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 2005, 42:S100-S107.
• [22]Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC: Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method¿analysis of 2010 Taiwanese patients. Eur J Cancer 2009, 45:1630-1639.
• [23]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(?Delta Delta C(T)) Method. Methods 2001, 25:402-408.
• [24]Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009, 115:4576-4585.
• [25]Guo X, Xiong L, Zou L, Zhao J: Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res 2012, 18:635-640.
• [26]Schmilovitz-Weiss H, Tobar A, Halpern M, Levy I, Shabtai E, Ben-Ari Z: Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study. Diagn Pathol 2011, 6:121. BioMed Central Full Text
• [27]Hong H, Patonay B, Finley J: Unusual reticulin staining pattern in well-differentiated hepatocellular carcinoma. Diagn Pathol 2011, 6:15. BioMed Central Full Text
• [28]Fisher RA: On the interpretation of ?2 from contingency tables, and the calculation of P. J R Stat Soc 1992, 85:87-94.
• [29]Wong KC: Chi squared test versus Fisher¿s exact test. Hong Kong Med J 2011, 17:427.
• [30]Stel VS, Dekker FW, Tripepi G, Zoccali C, Jager KJ: Survival analysis I: the Kaplan-Meier method. Nephron Clin Pract 2011, 119:c83-c88.
• [31]Zhang D, Quan H: Power and sample size calculation for log-rank test with a time lag in treatment effect. Stat Med 2009, 28:864-879.
• [32]Garcia RI, Ibrahim JG, Zhu H: Variable selection in the cox regression model with covariates missing at random. Biometrics 2010, 66:97-104.
• [33]Woo HH, Baker T, Laszlo C, Chambers SK: Nucleolin mediates microRNA-directed CSF-1 mRNA deadenylation but increases translation of CSF-1 mRNA. Mol Cell Proteomics 2013, 12:1661-1677.
• [34]Peng L, Liang J, Wang H, Song X, Rashid A, Gomez HF, Corley LJ, Abbruzzese JL, Fleming JB, Evans DB, Wang H: High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 2010, 16:3734-3742.